Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
HQ Team March 4, 2024: Obesity is widely recognized as a risk factor for cancer, and a recent study sheds light on an.
HQ Team November 9, 2023: Eli Lilly’s weight-loss injection Zepbound, to be taken along as a supplement with diet and exercise, got the.
HQ Team October 2, 2023: A drug that mimics the benefits of rigorous exercise has been developed on mice by scientists at the.
HQ Team June 20, 2023: Indian pharmaceutical company, Lupin Limited, has introduced its thiamine injection in the US market and has got FDA’s.
HQ Team June 8, 2023: A new study analyzing the PIONEER (Peptide Innovation for Early Diabetes Treatment) clinical trials data has revealed the.